M&A Deal Summary

Amneal Pharmaceuticals Acquires Saol Therapeutics - Baclofen Franchise

On January 5, 2022, Amneal Pharmaceuticals acquired life science company Saol Therapeutics - Baclofen Franchise

Acquisition Highlights
  • This is Amneal Pharmaceuticals’ 5th transaction in the Life Science sector.
  • This is Amneal Pharmaceuticals’ 6th transaction in the United States.
  • This is Amneal Pharmaceuticals’ 1st transaction in Georgia.

M&A Deal Summary
Date 2022-01-05
Target Saol Therapeutics - Baclofen Franchise
Sector Life Science
Buyer(s) Amneal Pharmaceuticals
Deal Type Divestiture

Target

Saol Therapeutics - Baclofen Franchise

Roswell, Georgia, United States
Saol Therapeutics' Baclofen Franchise is a pipeline product under development. Lioresal® is an intrathecal baclofen product delivered through an implantable intrathecal pump for use in the management of severe spasticity of cerebral or spinal origin for the institutional market. LYVISPAHTM is a baclofen oral granules (5, 10, and 20 mg) specialty product recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of spasticity.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Amneal Pharmaceuticals

Bridgewater, New Jersey, United States
Category Company
Founded 2002
Sector Healthcare Services
Employees7,850
Revenue 2.4B USD (2023)
DESCRIPTION

Amneal Pharmaceuticals manufactures and supplies generic pharmaceuticals. The company offers prescription pharmaceutical products in various forms, including oral solids that range from tablets to capsules and soft gels; and liquid-form pharmaceuticals that range from suspensions to solutions. Amneal Pharmaceuticals was incorporated in 2002 and is based in Bridgewater, New Jersey.

DEAL STATS #
Overall 6 of 6
Sector (Life Science) 5 of 5
Type (Divestiture) 2 of 2
State (Georgia) 1 of 1
Country (United States) 6 of 6
Year (2022) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-04-05 Kashiv Specialty Pharmaceuticals

Piscataway, New Jersey, United States

Kashiv Specialty Pharmaceuticals is a developer of complex generics, innovative drug delivery platforms and novel 505(b)(2) drugs. Kashiv Specialty Pharmaceuticals is based in Piscataway, New Jersey.

Buy -
Mergr

Product

Company

Legal